- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02199691
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
The purpose of the study was to evaluate the immunogenicity and describe the safety of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed vaccine MENVEO® in adolescents 10 to 17 years of age in the United States (US). This study also evaluated the immunogenicity and safety of MenACYW Conjugate vaccine when given alone compared to when given concomitantly with tetanus, diphtheria, acellular pertussis (Tdap) vaccine and human papilloma virus (HPV) vaccine.
Primary objective:
- To evaluate the antibody responses to the antigens present in MenACYW Conjugate vaccine when MenACYW Conjugate vaccine was given alone compared to those when MENVEO vaccine was given alone.
Secondary objective:
- To evaluate the antibody responses to the antigens present in MenACYW Conjugate vaccine, when MenACYW Conjugate vaccine was given concomitantly with Tdap and HPV vaccines, compared to those when it was given alone.
- To evaluate the antibody responses to the antigens present in Tdap vaccine, when Tdap vaccine was given concomitantly with MenACYW Conjugate vaccine and HPV vaccine, compared to those when Tdap vaccine was given with HPV vaccine only.
- To evaluate the antibody responses to the antigens present in HPV vaccine after the 3-dose series, when the first dose of HPV vaccine is given concomitantly with MenACYW Conjugate vaccine and Tdap vaccine, compared to those when the first dose of HPV vaccine is given with Tdap vaccine only.
Observational objective:
- To describe the safety profile of MenACYW Conjugate vaccine, compared to that of the licensed vaccine MENVEO®, and when MenACYW Conjugate vaccine was given with Tdap and HPV vaccines.
Study Overview
Status
Intervention / Treatment
- Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine
- Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine
- Biological: Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
- Biological: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
- Biological: GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00918
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35235
-
Huntsville, Alabama, United States, 35802
-
-
California
-
Downey, California, United States, 90241
-
San Diego, California, United States, 92103
-
-
Florida
-
Miami Beach, Florida, United States, 33141
-
-
Kansas
-
Wichita, Kansas, United States, 67205
-
-
Kentucky
-
Bardstown, Kentucky, United States, 40004
-
Nicholasville, Kentucky, United States, 40356
-
-
Maryland
-
Columbia, Maryland, United States, 21075
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68504
-
Lincoln, Nebraska, United States, 68505
-
Lincoln, Nebraska, United States, 68516
-
-
Ohio
-
Cleveland, Ohio, United States, 44121
-
Dayton, Ohio, United States, 45414
-
-
Oklahoma
-
Norman, Oklahoma, United States, 73069
-
-
Pennsylvania
-
Erie, Pennsylvania, United States, 16505
-
-
South Carolina
-
Charleston, South Carolina, United States, 29414
-
-
Tennessee
-
Kingsport, Tennessee, United States, 37660
-
Tullahoma, Tennessee, United States, 37388
-
-
Utah
-
Layton, Utah, United States, 84041
-
Orem, Utah, United States, 84057
-
Payson, Utah, United States, 84651
-
Provo, Utah, United States, 84064
-
Roy, Utah, United States, 84067
-
Salt Lake City, Utah, United States, 84109
-
Salt Lake City, Utah, United States, 84124
-
South Jordan, Utah, United States, 84095
-
Spanish Fork, Utah, United States, 84660
-
Syracuse, Utah, United States, 84075
-
West Haven, Utah, United States, 84401
-
West Jordan, Utah, United States, 84088
-
-
Virginia
-
Charlottesville, Virginia, United States, 22902
-
Midlothian, Virginia, United States, 23113
-
-
Washington
-
Spokane, Washington, United States, 99204
-
Spokane, Washington, United States, 99218
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 10 to 17 years on the day of inclusion.
- Informed consent form was signed and dated by the parent(s) or another legally acceptable representative.
- Assent form was signed and dated by the participant.
- Participant and parent legally acceptable representative were able to attend all scheduled visits and comply with all trial procedures.
Exclusion Criteria:
- Participant was pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination).
- Participation in the 4 weeks preceding the first trial vaccination(s) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
- Receipt of any vaccine in the 4 weeks preceding the first trial vaccination(s) or planned receipt of any vaccine in the 4 weeks prior to or following any trial vaccination except for influenza vaccination, which may be received at least 2 weeks before or after any study vaccines. This exception included monovalent influenza vaccines and multivalent influenza vaccines.
- Previous vaccination against meningococcal disease with either the trial vaccine or any mono- or polyvalent polysaccharide or conjugate meningococcal vaccine containing A, C, W, or Y antigens.
- History of vaccination with any tetanus, diphtheria, or pertussis vaccine within the previous 4 years.
- Previous human papilloma virus (HPV) vaccination.
- Receipt of immune globulins, blood or blood-derived products in the past 3 months.
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
- History of meningococcal infection, confirmed either clinically, serologically, or microbiologically.
- At high risk for meningococcal infection during the trial (i.e., participants with persistent complement deficiency, with anatomic or functional asplenia, or participants travelling to countries with high endemic or epidemic disease).
- Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances, including encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous pertussis antigen-containing vaccine.
- Personal history of Guillain-Barré syndrome.
- Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine within at least 10 years of the proposed study vaccination.
- Verbal report of thrombocytopenia, contraindicating intramuscular vaccination.
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination.
- Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
- Current alcohol abuse or drug addiction.
- Chronic illness (e.g., human immunodeficiency virus [HIV] hepatitis B, hepatitis C) that, in the opinion of the investigator, was at a stage where it might interfere with trial conduct or completion.
- Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature >= 100.4 degree fahrenheit [°F]). A prospective participant was not included in the study until the condition had resolved or the febrile event had subsided.
- Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
- Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1: MenACYW Conjugate Vaccine
Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine on Day 0.
|
0.5 milliliter (mL), Intramuscular (IM)
Other Names:
0.5 mL, Intramuscular (IM)
Other Names:
|
Active Comparator: Group 2: MENVEO® Vaccine
Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MENVEO® vaccine on Day 0.
|
0.5 mL, IM
Other Names:
|
Experimental: Group 3: MenACYW Conjugate Vaccine+Tdap+HPV
Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine, Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap), and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
|
0.5 milliliter (mL), Intramuscular (IM)
Other Names:
0.5 mL, Intramuscular (IM)
Other Names:
0.5 mL, IM
Other Names:
0.5 mL, IM
Other Names:
|
Active Comparator: Group 4: Tdap+HPV
Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of Tdap and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
|
0.5 mL, IM
Other Names:
0.5 mL, IM
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine
Time Frame: Day 30 (post-vaccination)
|
Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA.
The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers greater than or equal to (>=) 1:8 for participants with pre-vaccination hSBA titers less than (<) 1:8 or at least a 4-fold increase in hSBA titers from pre- to post vaccination for participants with pre-vaccination hSBA titers >= 1:8.
Data for this outcome measure was not planned to be collected and analyzed for Group 4:Tdap+HPV.
|
Day 30 (post-vaccination)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving hSBA Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines
Time Frame: Day 30 (post-vaccination on Day 0)
|
Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA.
The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers >= 1:8 for participants with pre-vaccination hSBA titers < 1:8 or at least a 4-fold increase in hSBA titers from pre- to post vaccination for participants with pre-vaccination hSBA titers >= 1:8.
|
Day 30 (post-vaccination on Day 0)
|
Geometric Mean Concentrations (GMCs) of PT, FHA, PRN, and FIM Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines
Time Frame: Day 30 (post-vaccination on Day 0)
|
Anti-Pertussis toxoid (PT), Filamentous hemagglutinin (FHA), Pertactin (PRN), and Fimbriae types 2 and 3 (FIM) antibodies were measured by enzyme-linked immunosorbent assay (ELISA).
|
Day 30 (post-vaccination on Day 0)
|
Percentage of Participants Achieving Anti-Tetanus and Anti-Diphtheria Concentrations >= 1.0 International Unit (IU)/mL Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines
Time Frame: Day 30 (post-vaccination on Day 0)
|
Anti-Diphtheria antibodies were measured by a toxin neutralization test.
Anti-Tetanus antibodies were measured by ELISA.
|
Day 30 (post-vaccination on Day 0)
|
Percentage of Participants Achieving Seroconversion for Anti-HPV6, HPV11, HPV16, and HPV18 Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines
Time Frame: Day 210 (post-vaccination on Day 0)
|
Anti-HPV 6, 11, 16, and 18 antibodies were measured using a competitive Luminex immunoassay.
Seroconversion was defined as changing serostatus from seronegative to seropositive.
Cutoff values for HPV seropositivity were >= 20 milli-Merck units per milliliter (mMU/mL) for types 6 and 16, >= 16 mMU/mL for type 11, and >= 24mMU/mL for type 18.
|
Day 210 (post-vaccination on Day 0)
|
Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With MenACYW Conjugate Vaccine or MENVEO® Vaccine at Day 0: Group 1 and Group 2
Time Frame: Within 7 days after vaccines injections at Day 0
|
A Solicited Reaction (SR) was an Adverse Event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction).
Solicited injection site reactions included: Pain, Erythema, and Swelling.
|
Within 7 days after vaccines injections at Day 0
|
Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines at Day 0: Group 3
Time Frame: Within 7 days after vaccines injections at Day 0
|
A SR was an AE that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction).
Solicited injection site reactions included: Pain, Erythema, and Swelling.
|
Within 7 days after vaccines injections at Day 0
|
Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With Tdap and HPV Vaccines at Day 0: Group 4
Time Frame: Within 7 days after vaccines injections at Day 0
|
A SR was an AE that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction).
Solicited injection site reactions included: Pain, Erythema, and Swelling.
|
Within 7 days after vaccines injections at Day 0
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Infections
- Central Nervous System Infections
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Meningitis, Bacterial
- Central Nervous System Bacterial Infections
- Neisseriaceae Infections
- Meningitis, Meningococcal
- Meningitis
- Meningococcal Infections
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- MET50
- U1111-1143-8537 (Other Identifier: WHO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meningitis
-
Prof. Elizabeth MillerNovartis VaccinesCompletedMeningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup WUnited Kingdom
-
University Hospital, Strasbourg, FranceCompleted
-
Assiut UniversityUnknown
-
University Medical Centre LjubljanaHarvard University; University of Ljubljana School of Medicine, Slovenia; Slovenian...Unknown
-
University of MinnesotaNational Institute of Neurological Disorders and Stroke (NINDS); Medical Research... and other collaboratorsCompletedCryptococcal Meningitis | Fungal MeningitisUganda
-
Rambam Health Care CampusWithdrawnGram Negative Meningitis | Post Traumatic Bacterial MeningitisIsrael
-
Charite University, Berlin, GermanyRecruitingBacterial Meningitis | Implant Infection | Fungal MeningitisGermany
-
Brigham and Women's HospitalActive, not recruitingPreventive Immunization; MeningitisUnited States
-
Matinas BioPharma Nanotechnologies, Inc.University of MinnesotaNot yet recruitingCryptococcal Meningitis
Clinical Trials on Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine
-
Sanofi Pasteur, a Sanofi CompanyRecruiting
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisUnited States, Puerto Rico
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisUnited States, Puerto Rico
-
SanofiCompletedMeningococcal Immunisation (Healthy Volunteers)Japan
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisFinland, Germany, Hungary, Spain
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisFinland
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningococcal Immunisation (Healthy Volunteers)Denmark, Finland, Germany
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisUnited States, Puerto Rico
-
Sanofi Pasteur, a Sanofi CompanyCompletedHealthy Volunteers (Meningococcal Infection)India, South Africa